The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Discovery of Potent and Selective Covalent Inhibitors of JNK
Open accessAbstract
The mitogen activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response. Here we report the discovery of the first irreversible inhibitors of JNK1/2/3. We describe two JNK3 co-crystal structures at 2.60 and 2.97 Å resolutions that show the compounds form covalent bonds with a conserved cysteine residue. JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK kinase, in cells exposed to sub-micromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggest that the compound will be broadly useful as a pharmacological probe of JNK-dependent signal transduction. Potential lead compounds have also been identified for kinases including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Kyriakis, J. M., & Avruch, J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.807 · Cited by 3,382
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Self-citationSP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 2×
“For example, one of the earliest and still most widely used inhibitors is the anthrapyrazolone, SP-600125 (Bennett et al., 2001; Figure 1A), which exhibits exceptionally low specificity for JNK (Bain et al., 2007) and should only be used in combination with other tools to rule out a potential role…”
MethodThe selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Quantitative reactivity profiling predicts functional cysteines in proteomes
Weerapana, E., Wang, C., Simon, G. M., Richter, F., Khare, S., Dillon, M. B. D., Bachovchin, D. A., Mowen, K., Baker, D., & Cravatt, B. F. (2010) · Nature · doi:10.1038/nature09472 · Cited by 1,684
Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487
Phosphorylation of c-jun mediated by MAP kinases
Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., & Woodgett, J. R. (1991) · Nature · doi:10.1038/353670a0 · Cited by 1,468
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430 · cited 2×
“In mammalian cells the MAPK signaling system is comprised of at least four distinct signaling modules defined by a core of MAP4K, MAP3K, MAP2K, and MAPKs that are named after the ‘‘terminal’’ MAPK in each pathway: ERK1/2, JNK1/2/3, p38a/b, and ERK5 (Chang and Karin, 2001; Johnson and Lapa- 140 Chemistry & Biology 19,…”
BackgroundRational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Self-citationNovel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Self-citationAguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010 · cited 1×
“JNK1 phosphorylates IRS-1, a key molecule in the insulinsensing pathway that downregulates insulin signaling, and JNK1 knockout mice are resistant to diet-induced obesity (Aguirre et al., 2000, 2002; Hirosumi et al., 2002; Sabio and ier Ltd All rights reserved (A) Representative JNK inhibitors.”
BackgroundHirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Kallunki, T., Su, B., Tsigelny, I., Sluss, H. K., Dérijard, B., Moore, G., Davis, R., & Karin, M. (1994) · Genes & Development · doi:10.1101/gad.8.24.2996 · Cited by 642
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
Zhang, Z., & Marshall, A. G. (1998) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(97)00284-5 · Cited by 509
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Signal transduction by tumor necrosis factor mediated by JNK protein kinases.
Sluss, H. K., Barrett, T., Dérijard, B., & Davis, R. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8376 · Cited by 459
Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 426
Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates
Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S., & Kozarich, J. W. (2007) · Biochemistry · doi:10.1021/bi062142x · Cited by 418
Self-citationIdentification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
Self-citationThe discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.054 · Cited by 289
Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269
Underwood, D. C., Osborn, R. R., Kotzer, C. J., Adams, J. L., Lee, J. C., Webb, E. F., Carpenter, D. C., Bochnowicz, S., Thomas, H. C., Hay, D. W. P., et al. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39230-4 · Cited by 241
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor
Thompson, J. E., Cubbon, R. M., Cummings, R. T., Wicker, L. S., Frankshun, R., Cunningham, B. R., Cameron, P. M., Meinke, P. T., Liverton, N., Weng, Y., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00106-3 · Cited by 234
High-throughput kinase profiling as a platform for drug discovery
Goldstein, D. M., Gray, N. S., & Zarrinkar, P. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2541 · Cited by 215
Self-citationp493F12 kinase: A novel MAP kinase expressed in a subset of neurons in the human nervous system
Mohit, A. A., Martin, J. H., & Miller, C. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90241-4 · Cited by 209
Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase
Atwell, S., Adams, J. M., Badger, J., Buchanan, M. D., Feil, I. K., Froning, K. J., Gao, X., Hendle, J., Keegan, K., Leon, B. C., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409792200 · Cited by 193
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, L.-H., Cellitti, J. F., Riel-Mehan, M., Emdadi, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805677105 · Cited by 186
Self-citationTargeted covalent drugs of the kinase family
Singh, J., Petter, R. C., & Kluge, A. F. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.168 · Cited by 177
cJun NH2-terminal kinase 1 (JNK1): Roles in metabolic regulation of insulin resistance
Sabio, G., & Davis, R. J. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.04.004 · Cited by 170
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
Schirmer, A., Kennedy, J., Murli, S., Reid, R., & Santi, D. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600445103 · Cited by 169
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N., & Traxler, P. M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00197-7 · Cited by 150
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 135
Self-citationResearch Article: Selectivity‐determining Residues in Plk1
Kothe, M., Kohls, D., Low, S., Coli, R., Rennie, G. R., Féru, F., Kuhn, C. F., & Ding, Y. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00594.x · Cited by 131
Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D. J., Cirillo, R., Gretener, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0310986 · Cited by 129
Mitogen‐activated protein kinases and asthma
Pelaia, G., Cuda, G., Vatrella, A., Gallelli, L., Caraglia, M., Marra, M., Abbruzzese, A., Caputi, M., Maselli, R., Costanzo, F. S., et al. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20169 · Cited by 120
Murata, T., Shimada, M., Sakakibara, S., Yoshino, T., Masuda, T., Shintani, T., Sato, H., Koriyama, Y., Fukushima, K., Nunami, N., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.041 · Cited by 120
Han, Z., Chang, L., Yamanishi, Y., Karin, M., & Firestein, G. S. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10104 · Cited by 116
Irreversible Nek2 Kinase Inhibitors with Cellular Activity
Henise, J., & Taunton, J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200222m · Cited by 96
Angell, R. M., Atkinson, F. L., Brown, M. J. B., Chuang, T. T., Christopher, J. A., Cichy-Knight, M. A., Dunn, A. K., Hightower, K. E., Malkakorpi, S., Musgrave, J. R., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.003 · Cited by 93
Inhibitors of the tyrosine kinase signaling cascade for asthma
Wong, W. S. F. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.009 · Cited by 90
Osto, E., Matter, C. M., Kouroedov, A., Maliñski, T., Bachschmid, M. M., Camici, G. G., Kılıç, Ü., Stallmach, T., Borén, J., Iliceto, S., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.765032 · Cited by 88
Targeting RSK: An Overview of Small Molecule Inhibitors
Nguyen, T. L. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914770 · Cited by 83
Kamenecka, T., Jiang, R., Song, X., Duckett, D. R., Chen, W., Ling, Y. Y., Habel, J. E., Laughlin, J. D., Chambers, J. W., Figuera-Losada, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901351f · Cited by 69
Self-citationAdaptive informatics for multifactorial and high-content biological data
Millard, B. L., Niepel, M., Menden, M. P., Muhlich, J. L., & Sorger, P. K. (2011) · Nature Methods · doi:10.1038/nmeth.1600 · Cited by 65
Self-citationSynthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors
Alam, M., Beevers, R. E., Ceska, T., Davenport, R. J., Dickson, K. M., Fortunato, M., Gowers, L., Haughan, A. F., James, L. A., Jones, M. W., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.078 · Cited by 62
Crocker, C. E., Khan, S., Cameron, M. D., Robertson, H. A., Robertson, G. S., & LoGrasso, P. V. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn1001107 · Cited by 56
Self-citationChialda, L., Zhang, M., Brune, K., & Pahl, A. M. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-36 · Cited by 54
Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants
Zhang, G., & Zhang, Q. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1373 · Cited by 44
Inhibitors of c-jun-N-Terminal Kinase (JNK)
LoGrasso, P. V., & Kamenecka, T. M. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708784912120 · Cited by 40
Self-citationHigh-throughput cellular assays for regulated posttranslational modifications
Robers, M. B., Horton, R. A., Bercher, M. R., Vogel, K. W., & Machleidt, T. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.09.012 · Cited by 30
Self-citationEmerging treatments for asthma
Blease, K., Lewis, A., & Raymon, H. K. (2003) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.8.1.71 · Cited by 30
Cited by
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Mitogen-activated protein kinases in innate immunity
Arthur, J. S. C., & Ley, S. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3495 · Cited by 1,855
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Self-citationJackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Metadata
- Authors
- Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., Laughlin, J. D., Park, H., LoGrasso, P. V., Patricelli, M., Nomanbhoy, T. K., Sorger, P. K., Alessi, D. R., & Gray, N. S.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 19
- Issue
- 1
- Pages
- 140-154
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2170444099
- Cited by
- 349
- References
- 63
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.